$ICAD
ICAD INC

2022 Q3 Form 10-Q Financial Statement

#000119312522221223 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $6.356M $7.575M $7.523M
YoY Change -32.1% -3.21% -12.93%
Cost Of Revenue $1.983M $2.084M $2.211M
YoY Change -25.14% -8.92% -6.31%
Gross Profit $4.373M $5.491M $5.312M
YoY Change -34.85% -0.85% -15.55%
Gross Profit Margin 68.8% 72.49% 70.61%
Selling, General & Admin $6.140M $6.177M $6.496M
YoY Change -6.17% 1.58% 16.42%
% of Gross Profit 140.41% 112.49% 122.29%
Research & Development $2.137M $2.367M $2.275M
YoY Change -6.48% 4.37% 3.88%
% of Gross Profit 48.87% 43.11% 42.83%
Depreciation & Amortization $130.0K $135.0K $139.0K
YoY Change -10.96% 2.27% -0.71%
% of Gross Profit 2.97% 2.46% 2.62%
Operating Expenses $8.333M $8.605M $8.834M
YoY Change -6.3% 2.33% 12.97%
Operating Profit -$3.960M -$3.114M -$3.522M
YoY Change 81.57% 8.46% 130.2%
Interest Expense $7.000K $0.00 -$9.000K
YoY Change 40.0% -100.0% -91.82%
% of Operating Profit
Other Income/Expense, Net $62.00K -$4.000K -$13.00K
YoY Change 1140.0% -99.02%
Pretax Income -$3.898M -$3.118M -$3.544M
YoY Change 79.14% -4.94% 116.1%
Income Tax $0.00 $0.00 $1.000K
% Of Pretax Income
Net Earnings -$3.898M -$3.118M -$3.545M
YoY Change 79.14% -4.94% 116.16%
Net Earnings / Revenue -61.33% -41.16% -47.12%
Basic Earnings Per Share -$0.15 -$0.12 -$0.14
Diluted Earnings Per Share -$0.15 -$0.12 -$140.9K
COMMON SHARES
Basic Shares Outstanding 25.33M 25.19M 25.16K
Diluted Shares Outstanding 25.20M 25.19M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.59M $27.18M $29.80M
YoY Change -31.32% -28.26% -36.48%
Cash & Equivalents $24.59M $27.18M $29.80M
Short-Term Investments
Other Short-Term Assets $2.203M $1.554M $1.916M
YoY Change 65.51% 55.4% 28.59%
Inventory $5.630M $5.001M $4.736M
Prepaid Expenses
Receivables $8.472M $10.17M $11.48M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $42.48M $45.31M $47.93M
YoY Change -19.66% -15.47% -22.99%
LONG-TERM ASSETS
Property, Plant & Equipment $986.0K $968.0K $1.806M
YoY Change -53.07% -57.75% -27.76%
Goodwill $8.362M $8.362M
YoY Change
Intangibles $535.0K $587.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $67.00K $55.00K $55.00K
YoY Change 21.82% 1.85% -38.89%
Total Long-Term Assets $12.90M $13.07M $10.91M
YoY Change 0.26% 0.86% -17.65%
TOTAL ASSETS
Total Short-Term Assets $42.48M $45.31M $47.93M
Total Long-Term Assets $12.90M $13.07M $10.91M
Total Assets $55.37M $58.38M $58.85M
YoY Change -15.76% -12.29% -22.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.423M $2.198M $2.681M
YoY Change -8.6% 111.55% 114.48%
Accrued Expenses $5.544M $5.271M $6.015M
YoY Change -13.09% -29.31% -9.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $14.60M $14.21M $14.46M
YoY Change -2.4% -1.76% 2.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.111M $3.179M $625.0K
YoY Change 227.13% 197.1% -51.17%
Total Long-Term Liabilities $3.111M $3.179M $625.0K
YoY Change 227.13% 197.1% -92.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.60M $14.21M $14.46M
Total Long-Term Liabilities $3.111M $3.179M $625.0K
Total Liabilities $17.72M $17.39M $15.09M
YoY Change 11.31% 11.94% -31.8%
SHAREHOLDERS EQUITY
Retained Earnings -$263.7M -$259.8M
YoY Change
Common Stock $302.8M $302.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.415M $1.415M
YoY Change
Treasury Stock Shares $185.8K $185.8K
Shareholders Equity $37.66M $40.99M $43.75M
YoY Change
Total Liabilities & Shareholders Equity $55.37M $58.38M $58.85M
YoY Change -15.76% -12.29% -22.05%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.898M -$3.118M -$3.545M
YoY Change 79.14% -4.94% 116.16%
Depreciation, Depletion And Amortization $130.0K $135.0K $139.0K
YoY Change -10.96% 2.27% -0.71%
Cash From Operating Activities -$2.651M -$2.560M -$4.449M
YoY Change 16.07% 26.92% 24.97%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$104.0K -$161.0K
YoY Change -12.28% 36.84% -38.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$104.0K -$161.0K
YoY Change -12.28% 36.84% -38.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 161.0K 46.00K 126.0K
YoY Change -48.73% -100.66% -99.46%
NET CHANGE
Cash From Operating Activities -2.651M -2.560M -4.449M
Cash From Investing Activities -100.0K -104.0K -161.0K
Cash From Financing Activities 161.0K 46.00K 126.0K
Net Change In Cash -2.590M -2.618M -4.484M
YoY Change 24.28% -71.0% -122.73%
FREE CASH FLOW
Cash From Operating Activities -$2.651M -$2.560M -$4.449M
Capital Expenditures -$100.0K -$104.0K -$161.0K
Free Cash Flow -$2.551M -$2.456M -$4.288M
YoY Change 17.56% 26.53% 29.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000749660
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address State Or Province
EntityAddressStateOrProvince
NH
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-09341
dei Entity Registrant Name
EntityRegistrantName
iCAD, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
02-0377419
dei Entity Address Address Line1
EntityAddressAddressLine1
98 Spit Brook Road, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Nashua
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
03062
dei City Area Code
CityAreaCode
603
dei Local Phone Number
LocalPhoneNumber
882-5200
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ICAD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Deferred Tax And Other Liabilities Noncurrent
DeferredTaxAndOtherLiabilitiesNoncurrent
5000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25333935
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27180000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34282000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
778000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
268000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10171000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8891000
CY2022Q2 us-gaap Inventory Net
InventoryNet
5001000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4171000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2953000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2962000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
45305000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
50306000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7275000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7106000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
968000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
882000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3102000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1059000
CY2022Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
55000
CY2021Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
899000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8820000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8724000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
587000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
683000
CY2022Q2 us-gaap Goodwill
Goodwill
8362000
CY2021Q4 us-gaap Goodwill
Goodwill
8362000
CY2022Q2 us-gaap Assets
Assets
58379000
CY2021Q4 us-gaap Assets
Assets
62191000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2198000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2779000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5271000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5642000
CY2022Q2 icad Lease Liability Current
LeaseLiabilityCurrent
566000
CY2021Q4 icad Lease Liability Current
LeaseLiabilityCurrent
889000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6171000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5652000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14206000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14962000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2598000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
266000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
581000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
441000
CY2022Q2 us-gaap Deferred Tax And Other Liabilities Noncurrent
DeferredTaxAndOtherLiabilitiesNoncurrent
4000
CY2022Q2 us-gaap Liabilities
Liabilities
17389000
CY2021Q4 us-gaap Liabilities
Liabilities
15674000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25373858
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25326086
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25188027
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25140255
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
254000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
253000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
301994000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
300859000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259843000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253180000
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
185831
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
185831
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1415000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1415000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40990000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
46517000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58379000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62191000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7575000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7826000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15098000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16470000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2084000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2288000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4295000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4643000
CY2022Q2 us-gaap Gross Profit
GrossProfit
5491000
CY2021Q2 us-gaap Gross Profit
GrossProfit
5538000
us-gaap Gross Profit
GrossProfit
10803000
us-gaap Gross Profit
GrossProfit
11827000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2367000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2268000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4642000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4460000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3435000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3429000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6853000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2742000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2652000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5673000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4803000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
61000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
60000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
124000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
115000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8605000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8409000
us-gaap Operating Expenses
OperatingExpenses
17439000
us-gaap Operating Expenses
OperatingExpenses
16231000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3114000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2871000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6636000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4404000
CY2022Q2 us-gaap Interest Expense
InterestExpense
0
CY2021Q2 us-gaap Interest Expense
InterestExpense
29000
us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
129000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-386000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-386000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-409000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-519000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3118000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3280000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6662000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4923000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24462000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24462000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
43753000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
33000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
309000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40990000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
46517000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
93000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
964000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3280000
us-gaap Net Income Loss
NetIncomeLoss
-6663000
us-gaap Net Income Loss
NetIncomeLoss
-4923000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25185000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25185000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24989000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24989000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25172000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25172000
us-gaap Net Income Loss
NetIncomeLoss
-6663000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40990000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
53364000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
365000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
67000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
511000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3280000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
51027000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30525000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23229000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
636000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
114000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1446000
icad Issuance Of Stock Upon Conversion Of Debentures
IssuanceOfStockUponConversionOfDebentures
7363000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
172000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16616000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7102000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10703000
us-gaap Net Income Loss
NetIncomeLoss
-4923000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
51027000
us-gaap Profit Loss
ProfitLoss
-6663000
us-gaap Profit Loss
ProfitLoss
-4923000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
105000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
115000
us-gaap Depreciation
Depreciation
169000
us-gaap Depreciation
Depreciation
157000
icad Noncashlease Expense
NoncashleaseExpense
391000
icad Noncashlease Expense
NoncashleaseExpense
388000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
510000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3000
us-gaap Share Based Compensation
ShareBasedCompensation
964000
us-gaap Share Based Compensation
ShareBasedCompensation
1446000
icad Amortization Accretion Of Discounts And Premiums
AmortizationAccretionOfDiscountsAndPremiums
0
icad Amortization Accretion Of Discounts And Premiums
AmortizationAccretionOfDiscountsAndPremiums
17000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-386000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1790000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
924000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
830000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-284000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-853000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-122000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-581000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1829000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-371000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-432000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-425000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-304000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
659000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-77000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-346000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-654000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7009000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5577000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
336000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-265000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-336000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
79000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
636000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
93000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
114000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23229000
icad Issuance Of Stock Upon Conversion Of Debentures
IssuanceOfStockUponConversionOfDebentures
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34282000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27186000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27180000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37889000
us-gaap Interest Paid Net
InterestPaidNet
9000
us-gaap Interest Paid Net
InterestPaidNet
92000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2434000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk and Uncertainty </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On March 12, 2020, the World Health Organization declared <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to be a pandemic. In an effort to contain and mitigate the spread of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the United States and most countries of the world have imposed some level of unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> As a provider of devices and services to the health care industry, the Company’s operations have been materially affected in all periods presented. Significant uncertainty remains as to the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the Company’s operations and on the global economy. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The <div style="white-space:nowrap;display:inline;">COVID-19</div> pandemic has resulted in significant financial market volatility and uncertainty. A continuing or worsening level of market disruption and volatility seen since the start of the pandemic will have an adverse effect on the Company’s ability to access capital, on the Company’s business, results of the Company’s operations and financial condition, and on the market price of the Company’s common stock. The Company’s results for the years ended December 31, 2021 and 2020, as well as all quarterly results beginning with the first quarter of 2020 through the second quarter of 2022, reflect a negative impact from the <div style="white-space:nowrap;display:inline;">COVID-19</div> pandemic, including but not limited to healthcare customers and potential customers providing additional focus on <div style="white-space:nowrap;display:inline;">COVID-19;</div> pandemic-related public health impacts, including significant shifts in workforce availability and priorities, on customer, supplier, and iCAD’s business processes; and effects on healthcare customers and potential customers of pandemic related supply chain issues. The Company’s quarterly expected results for the nine months ending September 30, 2022, or any interim or any future period could reflect a continuing negative impact from the <div style="white-space:nowrap;display:inline;">COVID-19</div> pandemic for similar or additional reasons. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">Although the Company has seen some impact to trade accounts receivable losses in the three and six months ended June 30, 2022 due to disruptions associated with the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, or other customer-specific factors. The Company has historically not experienced significant trade account receivable losses, but it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade account receivables as clinical customers’ cash flows are impacted by their response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic as well as public health considerations impacting their underlying businesses. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. For the fiscal year ended 2021, approximately 8.6% of the Company’s total revenue and approximately 39.0% of the Company’s export revenue was derived from customers located in Europe. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union, and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country’s potential response to such sanctions, tensions and military actions, is not knowable at this time, and could have a material adverse effect on the Company, </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">its business and operations. Any such material adverse effect from the conflict and enhanced sanctions activity may disrupt the Company’s sales to customers in the region. Prolonged unfavorable economic conditions or uncertainty may have an adverse effect on the Company’s sales and profitability. </div></div>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7575000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7575000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7575000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15098000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15098000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15098000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7826000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7826000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7826000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16470000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16470000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16470000
CY2022Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
10171000
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
8891000
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1399000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1895000
CY2022Q2 icad Contract With Customer Asset Non Current Net
ContractWithCustomerAssetNonCurrentNet
0
CY2021Q4 icad Contract With Customer Asset Non Current Net
ContractWithCustomerAssetNonCurrentNet
844000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6752000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6093000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6093000
icad Deferral Of Revenue
DeferralOfRevenue
6333000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-5674000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6752000
CY2021 icad Deferred Revenue To Be Recognized In Next Twelve Months
DeferredRevenueToBeRecognizedInNextTwelveMonths
4600000
CY2021Q4 icad Deferred Revenue To Be Recognized Year Two
DeferredRevenueToBeRecognizedYearTwo
3500000
CY2021Q4 icad Deferred Revenue To Be Recognized Year Three
DeferredRevenueToBeRecognizedYearThree
1300000
CY2021Q4 icad Deferred Revenue To Be Recognized Year Four
DeferredRevenueToBeRecognizedYearFour
1100000
CY2021 icad Deferred Revenue To Be Recognized Year Five
DeferredRevenueToBeRecognizedYearFive
100000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3280000
us-gaap Net Income Loss
NetIncomeLoss
-6663000
us-gaap Net Income Loss
NetIncomeLoss
-4923000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25185000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24989000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25172000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24462000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1819897
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2198220
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
300000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2549000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2962000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
218000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
173000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2503000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1279000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
5270000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
4414000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
269000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
243000
CY2022Q2 us-gaap Inventory Net
InventoryNet
5001000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4171000
icad Goodwill Impairment
GoodwillImpairment
0
icad Increase In Operating Lease Right Of Use Assets
IncreaseInOperatingLeaseRightOfUseAssets
2400000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
467000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
611000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
642000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
644000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
664000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
684000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
172000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3884000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
720000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3164000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
566000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2598000
CY2021Q2 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
7354283000
CY2021Q1 us-gaap Partners Capital Account Units Sale Of Units
PartnersCapitalAccountUnitsSaleOfUnits
1393738
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
18
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
25100000
CY2021Q1 us-gaap Partners Capital Account Public Sale Of Units Net Of Offering Costs
PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts
23200000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
309000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
511000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1446000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y11M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2486511
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.27
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3820000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
760000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.22
icad Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue
3000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28833
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
75000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
479797
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.33
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2737881
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.68
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
833000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1619855
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.47
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3730000
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1819897
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.44
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
830000
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2022Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
5100
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7575000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7826000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15098000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16470000
CY2022Q2 us-gaap Gross Profit
GrossProfit
5491000
CY2021Q2 us-gaap Gross Profit
GrossProfit
5538000
us-gaap Gross Profit
GrossProfit
10803000
us-gaap Gross Profit
GrossProfit
11827000
CY2022Q2 icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
-351000
CY2021Q2 icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
-198000
icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
-938000
icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
431000
CY2022Q2 icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
2763000
CY2021Q2 icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
2673000
icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
5698000
icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
4835000
CY2022Q2 us-gaap Interest Expense
InterestExpense
0
CY2021Q2 us-gaap Interest Expense
InterestExpense
29000
us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
129000
CY2022Q2 icad Interest Income
InterestIncome
14000
CY2021Q2 icad Interest Income
InterestIncome
19000
icad Interest Income
InterestIncome
16000
icad Interest Income
InterestIncome
33000
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
13000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
41000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
37000
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-386000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-386000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3118000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3280000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6662000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4923000
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
5100000
CY2022Q2 icad Minimum Royalty Obligations
MinimumRoyaltyObligations
200000

Files In Submission

Name View Source Status
0001193125-22-221223-index-headers.html Edgar Link pending
0001193125-22-221223-index.html Edgar Link pending
0001193125-22-221223.txt Edgar Link pending
0001193125-22-221223-xbrl.zip Edgar Link pending
d263616d10q.htm Edgar Link pending
d263616dex101.htm Edgar Link pending
d263616dex311.htm Edgar Link pending
d263616dex312.htm Edgar Link pending
d263616dex321.htm Edgar Link pending
d263616dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g263616g21p13.jpg Edgar Link pending
g263616g21p14.jpg Edgar Link pending
g263616g21p15.jpg Edgar Link pending
g263616g21p16.jpg Edgar Link pending
g263616g21p17.jpg Edgar Link pending
g263616g21p18.jpg Edgar Link pending
g263616g21p19.jpg Edgar Link pending
g263616g21p20.jpg Edgar Link pending
g263616g21p21.jpg Edgar Link pending
g263616g21p22.jpg Edgar Link pending
g263616g21p23.jpg Edgar Link pending
g263616g21p24.jpg Edgar Link pending
g263616g21p25.jpg Edgar Link pending
g263616g21p26.jpg Edgar Link pending
g263616g21p27.jpg Edgar Link pending
g263616g21p28.jpg Edgar Link pending
g263616g21p29.jpg Edgar Link pending
g263616g21p30.jpg Edgar Link pending
g263616g21p31.jpg Edgar Link pending
d263616d10q_htm.xml Edgar Link completed
g263616g21p32.jpg Edgar Link pending
g263616g21p33.jpg Edgar Link pending
g263616g21p34.jpg Edgar Link pending
g263616g21p35.jpg Edgar Link pending
g263616g21p36.jpg Edgar Link pending
g263616g37a01.jpg Edgar Link pending
g263616g38z36.jpg Edgar Link pending
g263616g39d25.jpg Edgar Link pending
g263616g40f32.jpg Edgar Link pending
g263616g41w25.jpg Edgar Link pending
g263616g42f25.jpg Edgar Link pending
g263616g43t52.jpg Edgar Link pending
g263616g44y63.jpg Edgar Link pending
g263616g45g66.jpg Edgar Link pending
g263616g46k25.jpg Edgar Link pending
g263616g47l25.jpg Edgar Link pending
g263616g48h11.jpg Edgar Link pending
g263616g49o25.jpg Edgar Link pending
g263616g50y22.jpg Edgar Link pending
g263616g51p36.jpg Edgar Link pending
g263616g52j26.jpg Edgar Link pending
g263616g53i25.jpg Edgar Link pending
g263616g54u23.jpg Edgar Link pending
g263616g55e63.jpg Edgar Link pending
g263616g56y25.jpg Edgar Link pending
g263616g57m22.jpg Edgar Link pending
g263616g58u24.jpg Edgar Link pending
g263616g59r63.jpg Edgar Link pending
g263616g60k85.jpg Edgar Link pending
g263616g61a98.jpg Edgar Link pending
g263616g62a98.jpg Edgar Link pending
g263616g63v98.jpg Edgar Link pending
g263616g64h98.jpg Edgar Link pending
g263616g65k98.jpg Edgar Link pending
g263616g66u98.jpg Edgar Link pending
g263616g67l58.jpg Edgar Link pending
g263616g68h58.jpg Edgar Link pending
g263616g69h58.jpg Edgar Link pending
g263616g70s58.jpg Edgar Link pending
g263616g71g58.jpg Edgar Link pending
g263616g72k58.jpg Edgar Link pending
g263616g73l58.jpg Edgar Link pending
g263616g74g58.jpg Edgar Link pending
g263616g75k58.jpg Edgar Link pending
g263616g76v58.jpg Edgar Link pending
g263616g77v58.jpg Edgar Link pending
g263616g78u58.jpg Edgar Link pending
g263616g79l66.jpg Edgar Link pending
icad-20220630.xsd Edgar Link pending
icad-20220630_def.xml Edgar Link unprocessable
icad-20220630_lab.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
icad-20220630_cal.xml Edgar Link unprocessable
icad-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable